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Abstract
Background: Presenting to care with advanced HIV is common in sub-Saharan Africa and increases the risk of
severe disease and death; however, it remains unclear whether this is a consequence of late diagnosis or a delay in
seeking care after diagnosis. The objectives of this cross-sectional study were to determine factors associated with
advanced HIV at presentation to care and whether this was due to late diagnosis or delays in accessing care.
Methods: Between 2013 and 2015, adults presenting to care were recruited at two clinics in low-income areas of
Nairobi, Kenya. Participants were considered to have advanced HIV if their CD4 count was below 200 cells/μL, or
they were in WHO stage 4. Information on previous HIV diagnoses was collected using interviewer-administered
questionnaires. Logistic regression was used to determine the association between clinical and socio-demographic
factors and advanced HIV.
Results: Of 753 participants presenting to HIV care, 248 (33 %) had advanced HIV. Almost 60 % (146/248) of those
presenting with advanced HIV had been previously diagnosed, most of whom (102/145; 70 %) presented to care
within three months of their initial diagnosis. The median time to presentation to HIV care after an initial diagnosis
was 22 days (IQR 6-147) for those with advanced HIV, compared to 19 days (IQR 4-119) for those with non-
advanced HIV (p = 0.716). Clinic (adjusted odds ratio [AOR] 1.55, 95 % CI 1.09–2.20) and age (AOR 1.72 per unit
increase in age category, 95 % CI 1.45–2.03) were associated with presenting with advanced HIV.
Conclusions: Presentation to care with advanced HIV was primarily due to delayed diagnosis, rather than delayed
linkage to care after diagnosis. Variation by clinic suggests that outreach and other community-based efforts may
drive earlier testing and linkage to care. Our findings highlight the ongoing importance of implementing strategies
to encourage earlier HIV diagnosis, particularly among adults 30 years and older.
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Despite increased HIV testing, improved global access
to antiretroviral therapy (ART), and changes in World
Health Organization (WHO) recommendations to ini-
tiate treatment earlier, the problem of presenting to
care with low CD4 counts persists across sub-Saharan
Africa. Those who present to care with a CD4 count
below 200 cells/μL, or an AIDS-defining event, are
considered to have advanced HIV disease [1]. Individ-
uals who initiate care with advanced HIV are more
likely to have impaired immune recovery [2] and re-
duced life expectancy [3]. Presenting with advanced
HIV may also result in higher direct medical and so-
cietal costs [4, 5], as well as an increased risk of on-
ward transmission [6]. Furthermore, high proportions
of individuals presenting with advanced HIV will im-
pede the UNAIDS 90-90-90 targets to have 90 % of
those living with HIV aware of their status; 90 % of
those diagnosed on treatment; and 90 % of those on
treatment virologically suppressed [7]. Understanding
risk factors for presentation to care with advanced
HIV is critical to developing strategies to encourage
earlier linkage to care and successful therapy.
While sub-Saharan Africa is disproportionately af-
fected by the HIV epidemic and persons present to care
with significantly lower CD4 counts than in other set-
tings [8, 9]; the majority of research on presentation to
care with advanced HIV has been conducted in higher-
resource settings. Of studies in sub-Saharan Africa, sev-
eral relied on routine clinical data, and although these
studies contributed important insights into presentation
to care with advanced HIV disease, they were unable to
capture data on important variables and suffered from
large amounts of missing data [10–12]. Other studies
have been limited by small sample size [12, 13], and
there have been contradictory findings on some of
the important determinants of presenting with ad-
vanced HIV, for example, age and alcohol use [9, 11,
12, 14, 15]. Furthermore, previous research in the re-
gion lacked data on timing of HIV diagnosis. There
has been a strong call to determine whether it is a
delay in diagnosis or a delay in seeking care after
diagnosis that leads to presentation to care with ad-
vanced HIV [9, 10, 16, 17]. Here, we conduct a cross-
sectional study of persons presenting at two clinics in
low-income areas of Nairobi, Kenya to evaluate the
pathway to presentation to care with advanced HIV
disease and its associated factors.
Objectives
(1)Quantify the proportion of individuals who first
present to care with advanced HIV.
(2)Determine whether presenting to care with
advanced HIV was due to delayed diagnosis or a
delay in seeking care after diagnosis.
(3)Determine factors associated with first presentation
to care with advanced HIV.
Methods
Study design
This cross-sectional study used baseline data collected
during a randomized controlled trial and supplemen-
tary cohort study. The trial involves evaluating the ef-
fectiveness of a text-messaging intervention to
improve retention in early HIV care [18]. Patients
who did not fulfil phone-related eligibility criteria for
the trial were invited to participate in a supplemen-
tary cohort study to examine patient retention during
the first year of HIV care. Adults testing positive for
HIV at two comprehensive care clinics in Nairobi,
Kenya were assessed for study eligibility.
Study setting and participants
Between April 2013 and June 2015, participants were re-
cruited from the Kibera Community Health Centre, an
Amref Health Africa clinic located in a large informal
settlement. At this comprehensive care clinic, there are
no direct patient costs for HIV care and treatment. The
population the clinic serves lacks or has minimal access
to services such as education, water, sanitation, or other
public services. HIV prevalence among adults tested for
the first time is estimated at 13 % [19]. In March 2014,
recruitment began at a second comprehensive care
clinic, the Baba Dogo Health Centre, which is situated in
another large informal settlement in Nairobi’s Eastlands
area and operated by the Kenya AIDS Control Project.
At each clinic, clinical staff introduced potential
participants to a research nurse, who completed an
eligibility assessment. Patients were eligible to partici-
pate in the study if they were 18 years old or older,
HIV-positive, and willing to provide informed con-
sent. Patients previously assessed for ART eligibility,
with prior ART exposure, or on ART were excluded.
Women known to be pregnant were also excluded.
Patients were screened for study participation at the
time of a positive HIV diagnosis, although potential
participants had one week to decide whether to enroll
in the study. Screened patients were a mixture of
those who: 1) presented to the clinic for HIV testing
and counselling (HTC) services; 2) sought treatment
for an illness and then the clinician referred them to
HTC; 3) had been diagnosed with HIV elsewhere and
presented to the clinic specifically to receive HIV
care.
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Outcomes
Presentation with advanced HIV disease
Presentation with advanced HIV disease was defined as
presenting with a CD4 count <200 cells/μL or at WHO
stage 4, regardless of CD4 count. This definition is based
on the consensus definition of advanced HIV disease,
which is presenting with a CD4 count <200 cells/μL or
an AIDS-defining event, regardless of CD4 count [1].
WHO Stage 4 was used as a proxy for AIDS-defining
events because of the overlap between AIDS-defining
conditions and the clinical events comprising WHO
stage 4 [20]. Presentation to care was defined as “attend-
ance at a health care facility that is able to monitor pro-
gression of HIV infection and initiate appropriate
medical care, including ART, as appropriate” [1].
Delay in seeking care
A delay in seeking care was defined as presenting to care
more than three months after a previous HIV diagnosis.
Determinants of presenting with advanced HIV disease and
potential effect modifiers
Variables were selected if there was prior strong evidence
of their association with advanced HIV disease at presen-
tation, e.g., sex (male or female) [9, 10, 14] and education
(some secondary versus no secondary) [9, 12, 14]; or if evi-
dence was conflicting, e.g., age (<30; 30–39; 40–49;
≥60 years) [9, 14, 21], travel time to the clinic (<30, 30–59,
≥60 min) [9, 14], and alcohol use (hazardous drinking ver-
sus non- hazardous drinking, [9, 12, 15] identified by the
AUDIT-C questionnaire score) [22]. We also investigated
a novel individual-level variable that may be a factor in
presenting with advanced HIV, current illicit drug use
(within 30 days of the baseline visit) e.g., heroin, cocaine,
etc. Since clinics are operated by different organizations
and serve different populations, clinic attended was also
considered (Baba Dogo v. Kibera). A priori information
was not available on potential interaction between
factors associated with presentation to care with ad-
vanced HIV; therefore, we explored plausible inter-
action between sex and travel to time to clinic, as an
interactive effect has been found in studies investigat-
ing retention in HIV care [23, 24].
Data sources and measurement
At the baseline visit, the research nurse administered a
questionnaire in the participant’s language of choice,
English or Kiswahili. Prior to starting recruitment, the
questionnaire was translated from English to Kiswahili,
back-translated, and pre-tested with clinic patients (n =
10). The questionnaire collected information on demo-
graphic characteristics, HIV testing history, and sub-
stance use. Blood was drawn at the baseline visit for
laboratory CD4 testing. HIV and CD4 testing were
consistent with routine clinical practice. Data were en-
tered in Microsoft Access on a weekly basis. Verification
procedures included cross-checking data files with ori-
ginal forms and clinical records, as well as range and
consistency checks.
Study size
A conservative rule is that logistic regression models
should have 10 outcome events per predictor variable to
build stable models [25]. A preliminary descriptive ana-
lysis indicated that there were 152 events of presentation
to care with advanced HIV in this cohort, [26] which
was adequate to build stable models with the six selected
factors.
Statistical methods
Descriptive analyses of the study population, including
the proportion of patients presenting with advanced
HIV disease, were conducted in SPSS v14. To com-
pare the time to presentation to care between ad-
vanced HIV and non-advanced HIV groups (for those
with a previous diagnosis), a Mann–Whitney U test
was used. Analyses were restricted to individuals with
complete data.
Logistic regression was used to determine factors asso-
ciated with advanced HIV at presentation to care. First,
univariable analyses were performed to assess the
strength of the association between each factor and the
outcome. Variables were then included in an initial mul-
tivariable model if they had a univariable p-value of
≤0.25 or were considered important based on prior evi-
dence (i.e., sex). In the final adjusted models, variables
were selected based on a significance threshold of p <
0.05. Nested models were compared using likelihood ra-
tio tests to examine interaction between sex and travel
time, and to determine whether to include a linear effect
or indicator variables for ordered categorical variables.
The fit of the final model was tested with the Hosmer-
Lemeshow goodness-of-fit test [27]. Results are pre-
sented as estimated odds ratios (OR) and adjusted ORs
(AOR) with corresponding 95 % confidence intervals
(CI) and p-values. All p-values are two-sided and re-
ported to three decimal places with those less than 0.001
reported as p < 0.001. Analyses were performed using
Stata version 12 (Statacorp, College Station, TX).
Ethics
The study protocol was approved by the University of
British Columbia’s Clinical Research Ethics Board
(H12-00563) and Amref Health Africa’s Ethics and
Scientific Review Committee (P40/12).
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Results
Study population
Between April 2013 and June 2015, 1068 HIV-positive
individuals presenting to the Baba Dogo and Kibera
Health Centres were screened for study participation,
and 775 were recruited (Fig. 1). The most frequent rea-
sons patients were ineligible to participate were previous
enrolment in HIV care (n = 160/262; 61 %) and preg-
nancy (n = 88/262; 34 %). Less than 3 % of screened par-
ticipants (n = 31/1068) declined participation. Of the 775
participants recruited, baseline CD4 data were available
for 97.2 % (n = 753/775) of the cohort.
The mean age of participants was 34 years (standard
deviation 9.82), and males comprised 40 % of the cohort.
Additional demographic and clinical characteristics are
summarized in Table 1. The median baseline CD4 count
was 302 cells/μL (IQR 148-463); 60.7 % (457/753) had a
CD4 count lower than 350 cells/μL. Approximately 1/3
(n = 248/753; 32.9 %) of the cohort presented to care
with advanced HIV (CD4 count <200 cells/μL or WHO
stage 4).
Late diagnosis versus delayed presentation to care
Of those who presented to care with advanced HIV, 146
(59 %) had been previously diagnosed with HIV. This
was similar to the proportion of those with a previous
diagnosis in the non-advanced HIV group (n = 306/505;
61 %; chi-square p-value 0.650). Most participants with
advanced HIV presented to care within three months of
their initial diagnosis (102/145; 70 %), including 44 indi-
viduals who presented within one week. Data on the
date of first HIV diagnosis was missing for one partici-
pant. The median time to presentation to HIV care after
an initial diagnosis was 22 days (IQR 6-147) for those
with advanced HIV, compared to 19 days (IQR 4-119)
for those with non-advanced HIV (p = 0.716).
Factors associated with presentation to care with
advanced HIV
Table 2 shows the association between clinical and
sociodemographic characteristics and presenting to care
with advanced HIV. In both univariable and multivari-
able analyses, age was linearly associated with presenting
to care with advanced HIV, with a final AOR of 1.72
(95 % CI 1.45 to 2.03) per unit increase in age category,
compared to the reference category of <30 years. Indi-
viduals presenting to the Baba Dogo clinic were more
likely to present with advanced HIV (AOR 1.55; 95 % CI
1.09–2.20) than those at the Kibera clinic. Those with
some secondary education were less likely to present
with advanced HIV; however this association was of bor-
derline significance in the final model (AOR 0.73; 95 %
CI 0.53–1.03). In the univariable analysis, male sex ap-
peared to be associated with presenting with advanced
HIV; however, this effect diminished in the multivariable
analysis and did not remain in the final model.
Discussion
Key results
In this cohort of individuals presenting to HIV care at
two clinics in Nairobi, Kenya, approximately one-third
presented to care with advanced HIV, suggesting import-
ant opportunities still exist to encourage earlier diagno-
sis and treatment. We found that delayed diagnosis was
more common than delayed linkage to care in explaining
presentation to care with advanced HIV. Although 59 %
of those presenting with advanced HIV had been previ-
ously diagnosed with HIV, almost ¾ of these individuals
presented to care within three months of their initial
diagnosis. Given the average rate of decline of CD4 T
lymphocytes [28, 29], it is unlikely that many of the indi-
viduals who presented to care with advanced HIV within
three months of their previous diagnosis would have had
non-advanced HIV when they were initially diagnosed.
Overall, there was a strong linear increase in the likeli-
hood of presenting with advanced HIV among age
groups older than 30. The proportion of those present-
ing with advanced HIV also varied by clinic, but this
may be expected as larger structural and contextual cor-
relates are likely to vary in different care settings. In this
instance, we noted that Baba Dogo lacks the same level
Fig. 1 Participant recruitment flow diagram
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of community outreach programs present in Kibera.
Community outreach programs in Kibera include home-
based HIV testing and counselling (HBTC) by various
organizations, including Amref Health Africa, Liverpool
VCT, and the Centers for Disease Control and Preven-
tion (CDC). Kibera also benefits from numerous clinics
at which HIV can be tested, including a Médicins Sans
Frontières (MSF) clinic that opened during the time of
recruitment for this study. While HBTC efforts exist in
Baba Dogo, they are less prevalent. These community-
based efforts may drive earlier testing and linkage to
care, and may have led to comparatively fewer clients
presenting with advanced HIV in Kibera.
Comparability with other studies
Various definitions of ‘advanced HIV disease’ have been
used in the literature, and the term has frequently been
used interchangeably with the term ‘late presentation’.
Definitions of ‘advanced HIV disease’ from studies in
sub-Saharan Africa have included: CD4 count <100
cells/μL or WHO stage 4 [10]; WHO stage 3 or 4 [9];
and CD4 < 100 cells/μL [14]. The wide array of defini-
tions used makes it difficult to compare the proportions
of individuals presenting to care with advanced HIV
across studies. For instance, in a large, multi-country
study by Lahuerta et al., 19 % of those enrolling in care
were classified as having advanced HIV [10], compared
to 33 % in our study; however, Lahuerta et al. used a
lower CD4 threshold of 100 cells/μL, so more individ-
uals might have been classified as having advanced HIV
than if a higher threshold of 200 cells/μL had been used.
The recent development of consensus definitions of ‘late
presentation’ (CD4 below 350 cells/μL or presenting
with an AIDS-defining event), ‘presentation with ad-
vanced HIV’, and even ‘presentation for care’ [1, 17], and
their use going forward, will facilitate comparison be-
tween studies in the future.
During the course of this study, the clinics transitioned
from initiating treatment at CD4 counts of 350 cells/μL
or less to the 2013 WHO’s recommendations to initiate
treatment at 500 cells/μL or lower [30]. The benefits of
which include improved survival, immune recovery, and
a decreased risk of transmission [30]. With approxi-
mately one-third of patients presenting to care with ad-
vanced HIV, and over half of the population presenting
with a CD4 count lower than 350 cells/μL, the majority
of patients at these clinics will not be affected by the
change in treatment guidelines, or more recent recom-
mendations to initiate treatment upon diagnosis, regard-
less of CD4 count. Over the past decade, CD4 count at
presentation has not markedly increased in sub-Saharan
Africa [7], and while it is too early to tell whether imple-
mentation of the new guidelines will promote earlier
presentation to care, our study emphasizes that it is
Table 1 Demographic and clinical characteristics of participants.
Values are numbers (percentages)
Variable Non-advanced HIV
at presentation to
care (n = 505)
Advanced HIV at
presentation to
care (n = 248)
Sex
Male 183 (61.4) 115 (38.6)
Female 322 (70.8) 133 (29.2)
Age (years)
Mean (SD) 32 (9.22) 37 (10.26)
<30 227 (79.9) 57 (20.1)
30–39 178 (62.9) 105 (37.1)
40–49 71 (57.7) 52 (42.3)
≥50 29 (46.0) 34 (54.0)
Education
No secondary school 327 (64.9) 177 (35.1)
Some secondary school 178 (71.5) 71 (28.5)
Clinic
Kibera 364 (68.4) 168 (31.6)
Baba Dogo 141 (63.8) 80 (36.2)
CD4
Median (IQR) (cells/μL) 389 (298–545) 90 (42–147)
≤350 210 (46.0) 247 (54.0)
>350 295 (99.7) 1 (0.3)
WHO Stage
1 356 (78.1) 100 (21.9)
2 72 (63.7) 41 (36.3)
3 57 (39.9) 86 (60.1)
4 0 (0.0) 8 (100.0)
Missing 20 (60.6) 13 (39.4)
Previous HIV diagnosis
No 199 (66.1) 102 (33.9)
Yes 306 (67.7) 146 (32.3)
Travel time to clinic
<30 min 236 (63.6) 118 (36.4)
30–59 min 219 (70.9) 90 (29.1)
≥60 min 77 (67.5) 37 (32.5)
Missing 3 (50.0) 3 (50.0)
Alcohol use
Non-heavy/hazardous drinking 356 (67.3) 173 (32.7)
Heavy/hazardous drinking 149 (66.5) 75 (33.5)
Illicit drug use
Not a current drug user 469 (66.4) 237 (33.6)
Current drug user 36 (76.6) 11 (23.4)
Abbreviations: SD standard deviation, IQR interquartile range
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critical to develop and implement strategies that en-
courage earlier diagnosis. Without this, stated targets
of expansion of therapy to those who are eligible and
the intended individual- and population-level effects
of the new WHO recommendations will not be fully
realised.
The importance of earlier diagnosis is further sup-
ported by our findings that presentation with advanced
HIV was largely due to delayed diagnosis, rather than a
delay in seeking care after diagnosis. Prior studies on
presentation with advanced HIV in the region did not
examine prior diagnoses [13], considered new diagnoses
only [14], or were based on clinical records [9, 10],
thereby restricting their ability to investigate the pathway
to presentation with advanced HIV. In addition to our
finding that approximately ¾ of those with advanced
HIV who had been previously diagnosed presented to
care within three months, the proportion of individuals
who had had a previous diagnosis was similar between
those with or without advanced HIV, and the median
time to first presentation to HIV care did not signifi-
cantly differ between the two groups. This supports our
conclusion that advanced HIV at first presentation was
primarily due to delayed diagnosis. This is not to under-
estimate the importance of promoting timely linkage to
care; however, as almost ¼ of those with advanced HIV
(who had been previously diagnosed) took longer than
three months to present to care, and many individuals
who test positive do not link to care [31, 32].
Similar to Kigozi et al. in their Ugandan study [9], we
found that older age was associated with advanced HIV
at presentation. This may be due to simply having lived
long enough for the disease to progress to an advanced
stage, or age-associated differences in HIV awareness,
knowledge or stigma that may affect testing and other
care-seeking behaviours [33]. Reducing the barriers to
and encouraging earlier diagnosis among older adults is
particularly important because of the smaller gains made
in CD4 response and increased risk of mortality
compared to younger age groups once ART is initiated
[33-35]. A study from South Africa found no association
with age and presentation with advanced HIV [15]; how-
ever, in the South African study, age was dichotomized
at 40 years, which may have underestimated the vari-
ation in risk according to age [36].
Although not statistically significant, relatively more
men than women presented to care with advanced HIV.
This is in contrast to other reports [9, 10, 14], which
found strong associations between male gender and
presentation with advanced disease. This may have been
due to the exclusion of pregnant women from this study.
In studies on CD4 at presentation to care, those with a
focus on prevention of mother-to-child transmission
(PMTCT) reported a higher mean CD4 count at presen-
tation (395 cells/μL) [7] than non-PMTCT-focussed
studies, and those enrolling in PMTCT services have
been found to have a lower likelihood of presenting with
advanced HIV disease than others [10]. By excluding
pregnant women in this study, the difference between
the genders in the risk of presenting with advanced HIV
may have been attenuated.
Other factors of interest, such as educational level [9, 12],
hazardous drinking [9, 12, 15], and travel time to
clinic [9], have been found to be associated with pres-
entation to care with advanced HIV in previous stud-
ies but were not in our cohort. There are several
possible explanations for this beyond the different
populations under study. First, the use of varying def-
initions of advanced HIV may underlie the differing
results: factors that are associated with advanced HIV
when a lower CD4 threshold is used may not be
similarly associated with advanced HIV when the con-
sensus definition is applied. Other possible explana-
tions include high levels of missing data in some
Table 2 Univariable and multivariable analysis of variables associated with presentation to care with advanced HIV disease
Crude ORs Adjusted ORs Final adjusted ORs
Variable OR 95 % CI p-value OR 95 % CI p-value OR 95 % CI p-value
Agea 1.66 1.41–1.96 <0.001 1.65 1.39–1.97 <0.001 1.72 1.45–2.03 <0.001
Presenting at the Baba Dogo clinic 1.23 0.88–1.71 0.220 1.53 1.08–2.17 0.018 1.55 1.09–2.20 0.014
Secondary education 0.74 0.53–1.03 0.070 0.69 0.49–0.98 0.040 0.73 0.52–1.03 0.073
Male gender 1.52 1.12–2.07 0.008 1.30 0.93–1.82 0.128
Illicit drug use 0.60 0.30–1.20 0.155 0.53 0.26–1.09 0.084
Hazardous drinking 1.04 0.74–1.44 0.835
Travel timeb 0.98 0.84–1.34 0.782
Previous HIV diagnosis 0.93 0.68–1.27 0.650
Abbreviations: OR odds ratio, CI confidence interval
aOR corresponds to an increase in the odds ratio per unit increase in age category (<30 years, 30–39 years, 40–49 years, ≥50 years)
bOR corresponds to an increase in the odds ratio per unit increase in travel time category (<30 min, 30–59 min, ≥60 min)
Hosmer-Lemeshow goodness-of-fit p = 0.199
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previous studies, which may have impacted findings;
investigation of a large number of variables, increas-
ing the likelihood of chance findings; and a larger
sample size in some of the previous studies, increas-
ing the power to detect effects.
Strengths and limitations of the study
One of this study’s principal strengths is our collection
of information on the date of participants’ first HIV
diagnosis, helping us to illuminate the pathway to pres-
entation to care with advanced HIV. A second major
strength of this study is the completeness of the data:
CD4 data was available for 97 % of the cohort, and infor-
mation on additional variables, such as alcohol or illicit
drug use, was available for all participants. Additional
strengths include a high participation rate, which mini-
mized the possibility of non-participation bias. This,
combined with the inclusion of two sites in the study,
improves this study’s generalizability.
We used a consensus definition of advanced HIV, part
of which is based upon presenting with an AIDS-
defining event regardless of CD4 count. WHO stage 4
was used as a proxy for AIDS-defining events. Although
most AIDS-defining conditions are included in WHO
stage 4, WHO staging data was only available for 85 %
of the cohort, which may have led to the misclassifica-
tion of some participants as non-advanced HIV. Further-
more, CD4 was measured at only one point in time.
Given laboratory variability in CD4 measurements, and
the possibility that other factors may temporarily influ-
ence CD4 counts [1], it would have been preferable to
have a confirmatory CD4 count.
Other limitations include the self-reported nature of
data on the occurrence and timing of prior HIV diagnoses.
There is a lack of data from Kenya on the validity of self-
reported HIV testing data; however, studies from other
parts of sub-Saharan Africa suggest that HIV-positive in-
dividuals may underreport past testing [37, 38]. While the
reasons for underreporting a previous diagnosis are not
well understood, one possibility is that individuals fear be-
ing turned away from the clinic if they indicate they are
aware of their status. At the study sites, care and treat-
ment guidelines were developed to protect clients from
being denied care. It is standard clinical practice to test all
patients who come to the clinics for HIV care, regardless
of whether they have been tested or diagnosed with HIV
before. These guidelines may encourage more honest
reporting on previous diagnoses than might otherwise
occur. To improve the quality of self-reported data, partic-
ipants completed the questionnaire after being assured of
confidentiality. In addition, the questionnaire was admin-
istered by an experienced HIV research nurse in a private
room. Finally, data from this section of the questionnaire
were cross-checked with a later section to assess
consistency. A high degree of consistency was found, and
any discrepancies were investigated further and resolved.
Despite the limitations inherent in self-reported data, the
study is unlikely to suffer from recall bias. There is no
strong reason to believe that the advanced HIV versus
non-advanced HIV groups would differentially report
events; however, data on the dates of previous HIV diag-
noses may be less valid than if we had had access to clin-
ical records.
Conclusions
Presentation to care with advanced HIV continues to
burden global HIV programs. In our study, this appeared
to be largely due to delayed diagnosis, rather than delays
in seeking care after diagnosis. The benefits of early HIV
care and treatment for both individual health reasons,
and population benefits through treatment as preven-
tion, are now widely accepted. Efforts are needed to
maximize earlier diagnosis and entry into care at the
front end of the HIV care continuum to fulfil new global
targets. Otherwise, changing guidelines to recommend
treatment earlier in the course of HIV infection will not
achieve their intended outcomes.
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